Take a look at this video, with a brief description of an umbilical hernia in a patient with cirrhosis.
About Dr. Joe GalatiDr. Joe Galati is a Liver Specialist practicing in Houston, Texas. His practice, Liver Specialists of Texas is dedicated to the care of patients with all facets of liver disease.
by Dr. Joe Galati on 04/20/2014
Tonight on Your Health First, I did a segment on alcohol use, and the ill effects on the body. This is information that needs to be shared with those closest to you. Unfortunately, not everyone is up to date on this information, and only after years of alcohol misuse and or abuse, do they come […]
by Dr. Joe Galati on 04/05/2014
Primary liver cancer, or hepatocellular carcinoma, is a growing problem we face in the care of patients with chronic liver disease, especially hepatitis C. The number of new cases of liver cancer I see each week has grown steadily over the past 15 years. A lot of this has to do with the aging population […]
by Dr. Joe Galati on 01/30/2014
A new article in the NEJM sheds light on the origins of obesity. It seems obesity starts earlier than expected, and obese 5 year olds are at risk for life-long obesity. Listen to Dr. Galati’s podcast here.
by Dr. Joe Galati on 12/08/2013
Last Friday the FDA gave approval to Gilead approving their new HCV drug sofosbuvir, know as Solvadi. The indication for the HCV drug is wider than ever before, opening the door to a much wider range of patients that can benefit from treatment. Know that it is available, feel free to contact us for a […]
by Dr. Joe Galati on 12/06/2013
Yet another new drug to treat hepatitis C has been approved. The FDA announced the approval of sofosbuvir, commercially known as Sovaldi. Sovaldi is manufactured by Gilead. More details on this new therapy will be added this weekend, so stay tuned. For an office evaluation and opinion if you are a candidate for these new hepatitis […]
by Dr. Joe Galati on 11/29/2013
This past week, the FDA gave approval to Janssen’s new drug to treat hepatitis C. Simeprevir, commercially know as OLYSIO, is the first new hepatitis C drug since the release of telapravir (Incevik) and boceprevir (Victrelis) in 2011. Simeprevir is a NS3/4A protease inhibitor, used in combination with interferon and ribavirin. The release of simeprevir marks […]
by Dr. Joe Galati on 11/23/2013
From our YouTube page, another example of a poor bowel prep. This man did not fully follow the instructions. When going for a colonoscopy, follow all directions as given, or else you’ll have to repeat the colonoscopy which is no fun.
by Dr. Joe Galati on 11/04/2013
This morning, Dr. Will Lee from UT Southwestern, gave a magnificent talk on acetaminophen (Tylenol) toxicity, and acute liver failure (ALF). Dr. Lee is an expert in this area, and has been studying acute liver injury for years. He and his colleagues have looked at acetaminophen toxicity nationwide, and have contributed greatly to our understanding. […]
by Dr. Joe Galati on 11/03/2013
Fatty liver disease is a hot topic here at the AASLD Annual Meeting. The complications of fatty liver including cirrhosis and liver cancer, and the central treatment strategy is weight loss. While bariatric surgery has been studies, presentations on less invasive therapies have been presented here at the meeting. Early results of a number of […]
- Telaprevir and FDA Approval: The Race is On for New Hepatitis C Drugs 02/28/2011
- The MELD Score and Liver Transplant: An Update for Patients 02/02/2011
- Waiting for a Liver Transplant: My MELD Score is Low-Now What? 06/14/2012
- The Great Mayonnaise Deception and Marketing Trickery 07/06/2014
- Alcoholic Liver Disease: What You Need to Know-The Basics 07/05/2014
- Childhood Obesity: A Close Up Look 06/29/2014
- Chuck Garcia: On a recent stroll through the supermarket aisles,...
- K Beecher: Hello. My husband was 24 to 48 hours away from dy...
- Firdous Ahmad: Dear Dr, My mother have hepatitis C, and she also ...